logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

Arcus Biosciences Arcus Biosciences ( RCUS ) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer and chronic inflammatory diseases, and other diseases. In partnership with firms and physicians around the world, Arcus...

Read More

August 23, 2023

0

The U.S. FDA Accepted Intellia Therapeutics IND Application of NTLA-5001 for Acute Myeloid Leukemia

Intellia Therapeutics IND Application of NTLA-5001 for AML is Accepted by the US FDA NTLA-5001 is Intellia Therapeutics ( NTLA ) first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. It is an autologous T cell...

Read More

September 16, 2021

0

Halozyme Therapeutics ENHANZE Reduces Roche's Tecentriq® Treatment Time to 7 Minutes from 30-60

Halozyme Therapeutics in the NEWS Halozyme Therapeutics ( HALO ) announced today that the Medicines and Healthcare Products Regulatory Agency ( MHRA ) in Great Britain has approved Roche's ( RHBBY ) subcutaneous Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug...

Read More

August 29, 2023

0

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly 

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals ( CRNX ) announced that its oral and once daily investigational compound paltusotine achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1...

Read More

September 11, 2023

0

Seagen Inc and Genmab Announce FDA Accelerated Approval for TIVDAK™ for Cervical Cancer

Seagen and Genmab Granted FDA Accelerated Approval for TIVDAK™ The U.S. FDA granted accelerated approval to Seagen Inc ( SGEN ) and  Genmab A/S ( GMAB ) product TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate ( ADC )...

Read More

September 21, 2021

0

CymaBay Therapeutics: New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

CymaBay Therapeutics in the NEWS CymaBay Therapeutics ( CBAY ) today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 ( IL-31 ) levels and its correlation with pruritus improvement in people with primary biliary cholangitis...

Read More

January 3, 2024

0

Encouraging News from Cassava Sciences

Cassava Sciences Announces Top-Line Clinical Data for Simulfilam Cassava Sciences Press Release Today Cassava Sciences ( SAVA ) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients...

Read More

September 22, 2021

0

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences ( NBIX ) announced positive top-line data from Phase 3 CAHtalystTM Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia ( CAH ) due...

Read More

September 12, 2023

0

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics ( ORTX ) - a global gene therapy firm, announced that the U.S. FDA has accepted the filing of its Biologics License Application ( BLA ) for OTL-200 in...

Read More

September 18, 2023

0

Reata Stock Holders Approved the Firm's Merger with Biogen

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary results indicate that the stockholders of the firm have voted to approve the Company’s previously announced acquisition (the “Merger”) by Biogen ( BIIB )...

Read More

September 21, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 147
  • 148
  • 149
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy